# STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

> **NCT07213570** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** standard second line treatment, at discretion of the investigator
- **DRUG:** Regorafenib (BAY73-4506)

## Key facts

- **NCT ID:** NCT07213570
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-16
- **Primary completion:** 2026-10
- **Final completion:** 2027-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213570, "STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07213570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*